Exxel Pharma Targets 2026 Clinical Start for Cough Drug EX937
| Field | Detail |
|---|---|
| Company | Exxel Pharma, Inc. |
| Form Type | S-1/A |
| Filed Date | Oct 14, 2025 |
| Risk Level | high |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $5.00, $11B, $2 billion, $11 billion |
| Sentiment | mixed |
Sentiment: mixed
Topics: Biotechnology, Pharmaceuticals, S-1/A Filing, Refractory Chronic Cough, FAAH Inhibitor, Clinical Trials, Early Stage Pharma
TL;DR
**Exxel Pharma is a high-risk bet on a single drug, EX937, in a massive, underserved market, but they need serious cash to even get off the ground.**
AI Summary
Exxel Pharma Inc., a biopharmaceutical company, is focused on developing EX937, a small-molecule FAAH inhibitor, for neuronal hypersensitivity disorders, with refractory chronic cough (RCC) as its lead indication. The company has completed IND-enabling studies for EX937 and targets first-in-human dosing in 2026 in Australia, pending capitalization and drug product manufacturing completion by Q4 2025. The global RCC market is estimated to reach $11 billion by 2027, impacting over 25 million people, and currently lacks FDA-approved treatments. Exxel Pharma holds exclusive worldwide development and commercialization rights for EX937, protected by patents potentially extending to 2044. The company also in-licensed the ARN program, another family of FAAH inhibitors, and is evaluating commercialization strategies for it. Exxel Pharma has incurred significant losses since inception and will require substantial additional capital to finance future operations, facing a going concern risk.
Why It Matters
Exxel Pharma's S-1/A filing signals its intent to enter the $11 billion refractory chronic cough market, a segment with no FDA-approved therapies, offering a potential new solution for over 25 million sufferers. For investors, this represents a high-risk, high-reward opportunity in a competitive biopharma landscape where companies like GSK have made significant acquisitions, such as the $2 billion purchase of Bellus Health. Employees and customers could benefit from the development of EX937, which aims to address a significant unmet medical need with a differentiated mechanism of action, potentially reducing side effects compared to existing off-label treatments. However, the company's limited operating history and need for substantial additional capital pose significant challenges.
Risk Assessment
Risk Level: high — The company has a limited operating history, has not initiated any clinical trials, and has no approved products for commercial sale, making its viability difficult to assess. Furthermore, Exxel Pharma has incurred significant losses since inception and its independent registered public accounting firm has expressed substantial doubt about its ability to continue as a going concern, indicating a critical need for additional capital to finance operations.
Analyst Insight
Investors should approach Exxel Pharma with extreme caution, recognizing the high speculative nature and significant capital requirements. Monitor closely for successful capital raises and the initiation of the planned Phase I/Ib clinical trial in 2026, as these milestones will be critical de-risking events for the company's lead candidate, EX937.
Key Numbers
- $11B — Estimated global market for Refractory Chronic Cough (RCC) (Expected market size by 2027, highlighting significant opportunity)
- 25 million — Estimated number of people globally impacted by RCC (Indicates the large patient population for EX937)
- 476,149 — Shares of common stock offered by selling shareholders (Represents the number of shares available for resale in this offering)
- $5.00 — Fixed price per share until listed on OTCQX or OTCQB (Initial offering price for the common stock)
- 2026 — Target year for first-in-human (FIH) dosing of EX937 (Key clinical development milestone for the lead product candidate)
- 2031/2032 — Composition of matter patent coverage for EX937 (Initial patent protection period in major pharmaceutical markets)
- 2044 — Potential extended composition of matter patent coverage for EX937 (Possible extension of patent protection through a pending application)
- $2 billion — Acquisition price of Bellus Health by GSK (Benchmark for potential value creation in the RCC market)
- 8 weeks — Duration defining refractory chronic cough (RCC) (Clinical definition of the lead indication for EX937)
- 5-10% — Estimated percentage of the general population suffering from RCC (Prevalence rate of the target disease)
Key Players & Entities
- Exxel Pharma Inc. (company) — Registrant and biopharmaceutical company
- EX937 (company) — Lead product candidate, small-molecule FAAH inhibitor
- Soren Mogelsvang (person) — Chief Executive Officer of Exxel Pharma Inc.
- Gary Joiner, Esq. (person) — Legal counsel from Frascona, Joiner, Goodman & Greenstein, PC
- Securities and Exchange Commission (regulator) — Regulatory body for the S-1/A filing
- University of California, Irvine (company) — Licensor of EX937 and ARN programs
- Merck (company) — Competitor with product Gefapixant
- GSK (company) — Acquirer of Bellus Health for $2 billion
- Bellus Health (company) — Acquired company with cough drug BLU-5973
- Frascona, Joiner, Goodman & Greenstein, PC (company) — Legal firm providing counsel
FAQ
What is Exxel Pharma Inc.'s primary focus?
Exxel Pharma Inc. is a biopharmaceutical company primarily focused on developing novel therapeutics for neuronal hypersensitivity disorders. Its lead product candidate, EX937, is being developed for refractory chronic cough (RCC), a condition affecting over 25 million people globally.
What is EX937 and how does it work?
EX937 is a proprietary, small-molecule therapeutic designed to selectively and peripherally inhibit the enzyme fatty acid amide hydrolase (FAAH). By blocking FAAH, EX937 increases levels of anandamide, which reduces the excitability of sensory neurons, thereby suppressing cough and potentially treating other hypersensitivity disorders.
What is the market potential for Exxel Pharma's lead indication, RCC?
The global market for refractory chronic cough (RCC) is estimated to reach $11 billion by 2027. This market represents a significant unmet medical need as there are currently no FDA-approved drugs available for this patient population.
What are the key upcoming milestones for Exxel Pharma?
Key upcoming milestones for Exxel Pharma include the completion of EX937 drug product manufacturing by Q4 2025 and the initiation of a two-part SAD/MAD (single ascending dose/multiple ascending dose) clinical trial in healthy human volunteers in 2026, planned for Australia.
What are the main risks associated with investing in Exxel Pharma?
Investing in Exxel Pharma involves high risks due to its limited operating history, absence of approved products, and significant accumulated losses. The company also faces a substantial doubt about its ability to continue as a going concern, requiring significant additional capital to fund future operations.
Who is the CEO of Exxel Pharma Inc.?
Soren Mogelsvang is the Chief Executive Officer of Exxel Pharma Inc. He is also listed as the agent for service for the company.
What is the patent protection status for EX937?
EX937 is protected by a comprehensive patent estate with composition of matter coverage in major pharmaceutical markets until 2031/2032, with potential for a 5-year patent term extension. A pending patent application could further extend this coverage until 2044.
Will Exxel Pharma receive proceeds from the sale of shares in this offering?
No, Exxel Pharma Inc. will not receive any of the proceeds from the sale of the 476,149 shares of common stock offered in this prospectus. These shares are being sold by existing selling shareholders.
What is the significance of Exxel Pharma being an 'emerging growth company'?
As an 'emerging growth company' under the Jumpstart Our Business Startups Act of 2012, Exxel Pharma has elected to comply with certain reduced public company reporting requirements in this prospectus and may continue to do so in future filings, which can lower compliance costs but may also provide less disclosure.
What is the ARN program mentioned by Exxel Pharma?
The ARN program, in-licensed from the University of California, Irvine, includes two families of globally active FAAH inhibitors, including the older URB597 and newer molecules with improved pharmacokinetic properties. Exxel Pharma is evaluating commercialization strategies for ARN, which has applications in CNS disorders like social anxiety and autism spectrum disorder.
Filing Stats: 4,379 words · 18 min read · ~15 pages · Grade level 14.6 · Accepted 2025-10-14 13:53:29
Key Financial Figures
- $5.00 — olders will be sold at a fixed price of $5.00 until our shares are quoted on the OTCQ
- $11B — ly and the market is estimated to reach $11B by 2027 1 . Key attributes of EX937, i
- $2 billion — the case of RCC, transactions like the $2 billion acquisition of Bellus Health by GSK pro
- $11 billion — Global RCC market is estimated to reach $11 billion by 2027 RCC affects approximately 5-1
Filing Documents
- ea0260195-s1a1_exxel.htm (S-1/A) — 1383KB
- ea026019501ex5-1_exxel.htm (EX-5.1) — 11KB
- ea026019501ex10-13_exxel.htm (EX-10.13) — 16KB
- ea026019501ex10-14_exxel.htm (EX-10.14) — 92KB
- ea026019501ex10-15_exxel.htm (EX-10.15) — 103KB
- ea026019501ex10-16_exxel.htm (EX-10.16) — 109KB
- ea026019501ex23-1_exxel.htm (EX-23.1) — 2KB
- image_001.jpg (GRAPHIC) — 3KB
- image_002.jpg (GRAPHIC) — 20KB
- image_003.jpg (GRAPHIC) — 121KB
- image_004.jpg (GRAPHIC) — 207KB
- image_005.jpg (GRAPHIC) — 159KB
- image_006.jpg (GRAPHIC) — 56KB
- image_007.jpg (GRAPHIC) — 57KB
- image_008.jpg (GRAPHIC) — 43KB
- image_009.jpg (GRAPHIC) — 125KB
- image_009a.jpg (GRAPHIC) — 69KB
- image_010.jpg (GRAPHIC) — 67KB
- image_011.jpg (GRAPHIC) — 107KB
- image_012.jpg (GRAPHIC) — 55KB
- image_013.jpg (GRAPHIC) — 31KB
- image_014.jpg (GRAPHIC) — 55KB
- image_015.jpg (GRAPHIC) — 176KB
- 0001213900-25-098577.txt ( ) — 3579KB
RISK FACTORS
RISK FACTORS 10 INDUSTRY AND MARKET DATA 46
USE OF PROCEEDS
USE OF PROCEEDS 47 DIVIDEND POLICY 47 SELLING STOCKHOLDERS 48 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 55 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 56
BUSINESS
BUSINESS 62 MANAGEMENT 81
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 88 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 91 PRINCIPAL SECURITYHOLDERS 92
DESCRIPTION OF CAPITAL STOCK
DESCRIPTION OF CAPITAL STOCK 93 SHARES ELIGIBLE FOR FUTURE SALE 94 PLAN OF DISTRIBUTION 96 LEGAL MATTERS 97 EXPERTS 97 WHERE YOU CAN FIND MORE INFORMATION 97 INDEX TO FINANCIAL STATEMENTS F-1 You should rely only on the information contained in this prospectus. We have not authorized anyone to provide you with different information and, if provided, such information or representations must not be relied upon as having been authorized by us. This prospectus shall not constitute an offer to sell or a solicitation of an offer to buy offered securities in any jurisdiction in which it is unlawful for such person to make such an offering or solicitation. You should read this prospectus together with the additional information described below under the heading “Where You Can Find More Information.” We may also provide a prospectus supplement or post-effective amendment to the Registration Statement to add information to, or update or change information contained in, this prospectus. The information contained in this prospectus, or any free writing prospectus is accurate only as of its date, regardless of its time of delivery or of any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. This prospectus does not contain all of the information included in the Registration Statement. For a more complete understanding of the offering of the securities, you should refer to the Registration Statement, including its exhibits. This prospectus includes our trademarks, and trade names, including but not limited to Exxel and Exxel Pharma, which are protected under applicable intellectual property laws. This prospectus also may contain trademarks, service marks, trade names, and copyrights of other companies, which are the property of their respective owners. Solely for convenience, the trademarks, service marks, trade names, and copyrights referred to in t